Balanced news tone
News Sentiment
DARE sentiment intelligence
Dare Bioscience Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-3.3% over one week, +0.0% over four weeks, trend active, and below fair value.
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Daré Bioscience CEO joins BIO 2026 panels on women’s health
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 12:00
- Source
- GlobeNewswire
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 May 2026 12:00
- Source
- GlobeNewswire
Earnings call transcript: Dare Bioscience outlines liquidity and revenue plans in Q1 2026
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 20 May 2026 07:00
- Source
- Investing.com UK
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 May 2026 12:00
- Source
- GlobeNewswire
Daré Bioscience begins phase 2 trial for HPV treatment By Investing.com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 May 2026 07:00
- Source
- Investing.com Nigeria
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 May 2026 05:03
- Source
- GuruFocus.com
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- GlobeNewswire
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Dare Bioscience completes closing of Regulation A offering of preferred stock and warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Investing.com
DARE Surges As Daré Bioscience Unveils Women’s Health Catalysts
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 19 Apr 2026 07:00
- Source
- StocksToTrade
DARE Bioscience Jumps As DARE to PLAY Launch and Pipeline Catalysts Draw Focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Apr 2026 07:00
- Source
- StocksToTrade
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 26 Mar 2026 07:00
- Source
- Market source
Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Feb 2026 08:00
- Source
- simplywall.st
Dare Bioscience (DARE) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 02:38
- Source
- Stock Titan
DARE Stock Price and Chart — NASDAQ:DARE
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2017 21:40
- Source
- TradingView